Pharmaceuticals France

France Dengue Vaccines Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

France Dengue Vaccines Market Industry Trends and Forecast to 2034: Segmented by (Product, Age, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

France · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $14.8 Mn Placeholder estimate
Estimate 2025 $17.6 Mn 2.5% of the global market
Projected 2034 $86.4 Mn 389.5% Adds $68.7 Mn over 9 forecast years
CAGR 2025–2034 19.3% Faster than 88% of 180 Pharmaceuticals markets here
Key players 5
  • France is 2.45% of the global market.
  • In Europe, the largest is Germany at $25.1 Mn.
  • Fastest growing: Italy at 19.6% a year.
  • France ranks 3rd of 6 by size in Europe.

Market size projection

France

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$68.7 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Dengue Vaccines Market market size by year, France
YearMarket sizeChange that yearSince 2025
2024 (estimate) $14.8 Mn — —
2025 (base) $17.6 Mn +$2.9 Mn —
2026 (forecast) $21.1 Mn +$3.4 Mn +19.3%
2027 (forecast) $25.1 Mn +$4.1 Mn +42.3%
2028 (forecast) $30.0 Mn +$4.8 Mn +69.8%
2029 (forecast) $35.7 Mn +$5.8 Mn +102.6%
2030 (forecast) $42.6 Mn +$6.9 Mn +141.7%
2031 (forecast) $50.9 Mn +$8.2 Mn +188.3%
2032 (forecast) $60.7 Mn +$9.8 Mn +243.9%
2033 (forecast) $72.4 Mn +$11.7 Mn +310.3%
2034 (forecast) $86.4 Mn +$14.0 Mn +389.5%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

France Dengue Vaccines Market Analysis at a glance
Market size, 2025$17.6 Mn placeholder estimate
Forecast, 2034$86.4 Mn placeholder estimate
Growth (CAGR), 2025–203419.3% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsProduct, age and end user (see all)
Key playersTakeda Pharmaceutical Company Ltd, Sanofi, Butantan Institute, Merck & Co., Inc., Panacea Biotec (see all)
Regulator in FranceANSMSource: ANSM, French medicines agency. Checked 14 Nov 2026.
Active clinical trials3 in FranceSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in France. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The France Dengue Vaccines Market Analysis Executive Summary

Dengue vaccines protect against dengue fever, a mosquito-borne disease spreading fast in tropical and warming regions.

Key segments of the dengue Vaccines market include product (Live Attenuated Vaccines and Candidate Vaccines) and age (Children, Adolescents and Adults).

Bar chart: France Dengue Vaccines market size, 2024–2034, placeholder estimates. $14.8 Mn in 2024, $17.6 Mn in 2025 and $86.4 Mn in 2034, 19.3% CAGR.
France Dengue Vaccines market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

France Dengue Vaccines Market Dynamics

Market Growth Drivers

Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the dengue Vaccines market.

Opportunity

New vaccines, rapid tests and public-private funding for neglected diseases give the dengue Vaccines market room to grow, especially in Asia, Africa and Latin America.

Market Restraints

Low prices in poorer markets, weak returns for new antibiotics, vaccine hesitancy and cold-chain problems hold back the dengue Vaccines market.

Competitive Landscape for Dengue Vaccines Market in France

The dengue Vaccines market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Dengue Vaccines Market in France

Dengue Vaccines in France: rules, payment and research

Medicines are authorised either for the whole EU by the European Commission, after review by the European Medicines Agency (EMA), or nationally by ANSM, the French medicines agency.⁠[1] National health insurance (Assurance Maladie) pays back part of most care costs, and the HAS, the French National Authority for Health, advises on what it should cover.⁠[2] ClinicalTrials.gov lists 3 studies on Dengue Vaccines that are recruiting, active or about to start in France.⁠[3]

[1] ANSM, French medicines agency. Checked 14 Nov 2026.

[2] Assurance Maladie (ameli.fr). Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in France. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for dengue Vaccines. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in France.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Dengue Vaccines right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Dengue Vaccines in context

France compared

  • Health spending per person: 5,327 US$ per person (2024). World: 1,317 US$ per person (2023). 3rd highest of the 6 countries we cover in Europe.[1]
  • Doctors: 3.28 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 6th highest of the 6 countries we cover in Europe.[2]
  • People aged 65 and over: 22.5% of people (2025). World: 10.4% of people (2025). 3rd highest of the 6 countries we cover in Europe.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 15 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 16 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 16 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Dengue Vaccines market in France?
Placeholder estimate: about $17.6 Mn in 2025, rising to about $86.4 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Dengue Vaccines market in France growing?
Placeholder estimate: about 19.3% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Dengue Vaccines market report cover?
The report splits the market by product (Live Attenuated Vaccines, Candidate Vaccines), age (Children, Adolescents, Adults) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Dengue Vaccines market?
Key players include Takeda Pharmaceutical Company Ltd, Sanofi, Butantan Institute, Merck & Co., Inc. and Panacea Biotec.
What is driving the Dengue Vaccines market?
Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the dengue Vaccines market.
Who regulates Dengue Vaccines in France?
Medicines are authorised either for the whole EU by the European Commission, after review by the European Medicines Agency (EMA), or nationally by ANSM, the French medicines agency. Source: ANSM, French medicines agency. Checked 14 Nov 2026.
How is healthcare paid for in France?
National health insurance (Assurance Maladie) pays back part of most care costs, and the HAS, the French National Authority for Health, advises on what it should cover. Source: Assurance Maladie (ameli.fr). Checked 14 Nov 2026.
How many clinical trials on Dengue Vaccines are running in France?
3 studies are recruiting, active or about to start in France, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in France. Retrieved 12 Nov 2026.
How much research is published on Dengue Vaccines?
PubMed lists 165 papers on Dengue Vaccines added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in France

See all

Related on vaccines and infectious diseases

See the topic